Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-α therapy

British Journal of Haematology

Volumn 101, Issue 3, 1998, Pages 552-557

  Tchirkov, Andrei ^a,d   Giollant, Michel ^a   Tavernier, Françoise ^b   Briançon, Georges ^a   Tournilhac, Olivier ^b   Kwiatkowski, Fabrice ^c   Philippe, Pierre ^b   Choufi, Bachra ^c   Deméocq, François ^b   Travade, Philippe ^b   Malet, Paul ^a  

^a ONERA   (France)

^b HÔTEL DIEU   (France)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

BCR ABL gene; CML; Competitive RT PCR; Interphase FISH; Response to interferon

Indexed keywords

ALPHA INTERFERON;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DEFICIENCY; INTERPHASE; KARYOTYPE; MALE; METAPHASE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON-ALPHA; INTERPHASE; LEUKEMIA, MYELOID, AGGRESSIVE-PHASE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 7144256540     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00717.x     Document Type: Article

References (14)

1. Amiel, A., Yarkoni, S., Slavin, S., Or, R., Loberboum-Galski, H., Fejgin, M. & Nagler, A. (1994) Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 76, 59-64.
2. Bentz, M., Cabot, G., Moos, M., Speicher, M.R., Ganser, A., Lichter, P. & Dohner, H. (1994) Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood, 83, 1922-1928.
3. Cross, N.C.P., Lin, F., Chase, A., Bungey, J., Hughes, T.P. & Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 1929-1936.
4. Hochhaus, A., Lin, E, Reiter, A., Skladny, H., Mason, P.J., van Rhee, F., Shepherd, P.C.A., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1996) Quantification or residual disease in chronic myeloid leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood, 87, 1549-1555.
5. Hochhaus, A., Lin, F., Reiter, A., Skladny, H., van Rhee, F., Shepherd, P.C.A., Allan, N.C., Hehlmann, R., Goldman, J.M. & Cross, N.C.P. (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieved complete cytogenetic remission with interferon-α. British Journal of Haematology, 91, 126-131.
6. Hochhaus, A., Yan, X.H., Willer, A., Hehlman, R., Gordon, M.Y., Goldman, J.M. & Melo, J.V. (1997) Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukemia. Leukemia, 11, 933-939.
7. Kantarjian, H.M., Deisseroth, A., Kurzrock, R., Estrov, Z. & Talpaz, M. (1993) Chronic myelogenous leukemia: a concise update. Blood, 82, 691-703.
8. Kantarjian, H.M., Smith, L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Annals of Internal Medicine, 122, 254-261.
9. Lin, F., Chase, A., Bungey, J., Goldman, J.M. & Cross, N.C.P. (1995) Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukemia. Genes, Chromosomes and Cancer, 13, 110-114.
10. Lin, F., Goldman, J.M. & Cross, N.C.P. (1994) A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. British Journal of Haematology, 86, 683-685.
11. Seong, D.C., Kantarjian, H.M., Ro, J.Y., Talpaz, M., Xu, J., Robinson, J.R., Deisseroth, A.B., Champlin, R.E. & Siciliano, M.J. (1995) Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood, 86, 2343-2349.
12. Stock, W., Westbrook, C.A., Peterson, B., Arthur, D.C., Szatrowski, T.P., Silver, R.T., Sher, D., Wu, D., Le Beau, M.M., Schiffer, C.A. & Bloomfield, C.D. (1997) Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 15, 26-36.
13. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
14. Van Rhee, F., Marks, D.I., Lin, F., Szydlo, R.M., Treleaven, J., Hochhaus, A., Delord, C., Cross, N.C.P. & Goldman, J.M. (1995) Quantification of residual disease in Philadelphia positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia, 9, 329-335.